FDA "informal" rulemaking ban proposed by House Budget Committee.
This article was originally published in The Gray Sheet
FDA "INFORMAL RULEMAKING" PROHIBITION PROPOSED BY HOUSE BUDGET CMTE. in its report on the fiscal year 1996 budget resolution. "The FDA currently makes policy through a variety of improper means" such as "points to consider," draft guidances, speeches and warning letters, according to the report. These activities, which "are difficult to track, yet often contain substantive rules," should be eliminated by withholding funding for them through the appropriations process, the committee says.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.